Premarin/MPA 0.45 mg/1.5 mg

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
32
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postmenopause

Conditions

Postmenopause

Trial Timeline

May 1, 2007 โ†’ Aug 1, 2007

About Premarin/MPA 0.45 mg/1.5 mg

Premarin/MPA 0.45 mg/1.5 mg is a phase 1 stage product being developed by Pfizer for Postmenopause. The current trial status is completed. This product is registered under clinical trial identifier NCT00472927. Target conditions include Postmenopause.

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00472927Phase 1Completed